Background Nucleophosmin/nucleoplasmin 3(NPM3),a member of the NPM protein family,is widely expressed in various human tissues.Although previous studies identified elevated NPM3 expression in several cancers,a systema...Background Nucleophosmin/nucleoplasmin 3(NPM3),a member of the NPM protein family,is widely expressed in various human tissues.Although previous studies identified elevated NPM3 expression in several cancers,a systematic pan-cancer analysis remains lacking.In this study,we conducted a comprehensive analysis of NPM3 to determine its role in tumorigenesis and tumor development.Methods Using data from The Cancer Genome Atlas(TCGA)and various bioinformatics analysis tools,we conducted a pan-cancer analysis of NPM3.Additionally,we collected gene expression and clinical data from 890 patients with lung adenocarcinoma(LUAD)from TCGA and the Gene Expression Omnibus database.We performed Cox regression analyses to explore the independent prognostic value of NPM3 expression in LUAD and plotted a nomogram to predict patient survival.We also used real-time quantitative polymerase chain reaction(RT-qPCR)to examine the expression levels of NPM3 in seven pairs of LUAD and paraneoplastic tissue samples.Results NPM3 expression was significantly increased in 20 types of cancer and was associated with poor prognosis in five types(P<0.05).NPM3 expression was negatively correlated with DNA methylation and positively correlated with copy number variation.NPM3 was also significantly associated with immune cell infiltration in various cancers.Cox regression analyses revealed that NPM3 expression could serve as an independent prognostic marker of LUAD.Moreover,our nomogram demonstrated good predictive ability for the prognosis of patients with LUAD.Finally,the high expression of NPM3 in LUAD was verified using RT-qPCR.Conclusion NPM3 is a promising biomarker for predicting pan-cancer prognosis and immunotherapeutic efficacy.展开更多
基金This study was supported by the National Natural Science Foundation of China(No.82172620)the Nature Science Foundation of Tianjin City(No.18JCZDJC98800).
文摘Background Nucleophosmin/nucleoplasmin 3(NPM3),a member of the NPM protein family,is widely expressed in various human tissues.Although previous studies identified elevated NPM3 expression in several cancers,a systematic pan-cancer analysis remains lacking.In this study,we conducted a comprehensive analysis of NPM3 to determine its role in tumorigenesis and tumor development.Methods Using data from The Cancer Genome Atlas(TCGA)and various bioinformatics analysis tools,we conducted a pan-cancer analysis of NPM3.Additionally,we collected gene expression and clinical data from 890 patients with lung adenocarcinoma(LUAD)from TCGA and the Gene Expression Omnibus database.We performed Cox regression analyses to explore the independent prognostic value of NPM3 expression in LUAD and plotted a nomogram to predict patient survival.We also used real-time quantitative polymerase chain reaction(RT-qPCR)to examine the expression levels of NPM3 in seven pairs of LUAD and paraneoplastic tissue samples.Results NPM3 expression was significantly increased in 20 types of cancer and was associated with poor prognosis in five types(P<0.05).NPM3 expression was negatively correlated with DNA methylation and positively correlated with copy number variation.NPM3 was also significantly associated with immune cell infiltration in various cancers.Cox regression analyses revealed that NPM3 expression could serve as an independent prognostic marker of LUAD.Moreover,our nomogram demonstrated good predictive ability for the prognosis of patients with LUAD.Finally,the high expression of NPM3 in LUAD was verified using RT-qPCR.Conclusion NPM3 is a promising biomarker for predicting pan-cancer prognosis and immunotherapeutic efficacy.
